Potential supply chain disruption in healthcare industry due to Trump tariffs may impact stocks negatively.

From Zacks Investment Research: 2025-04-09 16:04:00

The Trump administration’s new tariff policy is reshaping American trade, impacting the healthcare industry. Pharmaceuticals are exempt from steep tariffs, but the broader healthcare ecosystem faces potential supply chain disruption. Investors seeking stability may turn to large-cap U.S.-based stocks like Universal Health Services, BioMarin Pharmaceutical, and Abbott Laboratories.

Pharmaceuticals have dodged increased tariffs, saving $200 billion in annual imports. However, a proposed 25% tariff on foreign-made drugs could lead to pricing pressure. Medical devices and healthcare supplies are feeling the tariff impact, with industry warnings of delayed innovation and rising costs.

Goldman Sachs raises the odds of a U.S. recession to 45%, citing trade uncertainty. Retaliation from trade partners like the EU and China may further limit access to materials and technologies.

Investors are advised to focus on large-cap and fundamentally strong healthcare stocks like Universal Health Services, BioMarin Pharmaceutical, and Abbott Laboratories. These companies are well-positioned to navigate economic and geopolitical challenges.



Read more at Zacks Investment Research: Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On – April 9, 2025